Skip to main content

Rett In The News

The Washington Post
The long wait for vaccination has left many people across the country feeling anxious, desperate even. But for the young and disabled, and for the people who care about them, the realization of where they fall on priority lists has also left them feeling disregarded and discarded.
Global Genes
Global Genes interviews Monica Coenraads as part of their Rare Disease efforts.
BioSpace
Taysha Gene Therapies, Inc. has highlighted its strategic priorities and provided a business outlook for 2021.
Neurogene
Neurogene Inc. has announced a collaboration to advance development of multiple platform approaches designed to enable next generation gene therapies.
Spectrum
Two unpublished studies detail improved methods for delivering gene therapies to the brain: One involves a type of stem cell that can produce gene-altering proteins on-site; the other taps an engineered virus to target neurons efficiently and noninvasively.
The New York Times
Clusters of living brain cells are teaching scientists about diseases like autism. With a new finding, some experts wonder if these organoids may become too much like the real thing.
Spectrum
A gene therapy for Angelman syndrome stands at the forefront of efforts to treat autism-linked conditions that stem from single genes.
THE LATEST
October is Rett Syndrome Month. It's a rare and very challenging disease that affects just one in 10,000 girls. It's a tough go, but there is hope. Tim Freeman from the Rett Syndrome Research Trust tells us more.
Spectrum
Problems with the formation of DNA-filled droplets that control gene expression may contribute to Rett syndrome, a new study suggests.
Taysha Gene Therapies
Taysha Gene Therapies, a patient-centric gene therapy company with a mission to eradicate monogenic CNS disease, today announced that it has closed an oversubscribed $95 million Series B financing with a premier syndicate of life science investors, led by Fidelity Management & Research ...
Vico Therapeutics
Vico Therapeutics, a Leiden, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, today announced that it has raised $31 million (€27 million) in a Series A financing round.
OHSU News
OHSU study first to use programmable RNA editing to repair gene that contributes to Rett syndrome.
The New York Times
Our executive director, Monica Coenraads, and her daughter are featured on the front page of the NYT science section.
STAT
The coronavirus pandemic has stretched hospital resources beyond their capacity, disrupted the delivery of care, and drained providers of billions of dollars of revenue for canceled elective procedures, office visits, and tests.
Lundbeckfonden
The world's largest brain research prize is Danish and is awarded by the Lundbeck Foundation. Each year, we award 10 million DKK (approx. 1,3 million€) to one or more brain researchers who have had a ground-breaking impact on brain research.
The New York Times
There’s more than meets the eye — here are some tips to help avoid confusion.
The Scientist
When X-linked genes evade silencing on the “inactive” chromosome in XX cells, some protect women from diseases such as cancer, but others seem to promote conditions such as autoimmunity.
Biocompare
Gene or genome editing describes a process by which targeted and deliberate changes to the DNA sequence are made. Recent advances in programmable nucleases, including the CRISPR-Cas9 system, mean that manipulating DNA has never been easier, which could fundamentally alter the way we treat and ...
Nature
Making changes to the molecular messengers that create proteins might offer flexible therapies for cancer, pain or high cholesterol, in addition to genetic disorders.
GEN
GEN invites its readers to gaze into the crystal ball that is the January 2020 issue.
MIT Technology Review
Researchers have developed “prime editing,” a true search-and-replace function for DNA.
Spectrum
Austrian pediatrician Andreas Rett first recognized the syndrome that would later bear his name in the mid-1960s. The first description in English, published in 1983, detailed a “progressive syndrome of autism” and other traits in 35 girls.